Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343453 | 0.83 | CYP3A4 (0.46) | CYP3A4ALDH1A1TSHRLMNAALOX15 | |
| SCHEMBL5878424 | 0.80 | CYP3A4 (0.36) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL11908183 | 0.78 | CYP3A4 (0.42) | CYP3A4ALDH1A1TSHRLMNAALOX15 | |
| SCHEMBL13224500 | 0.78 | CYP3A4 (0.55) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL5878418 | 0.77 | TSHR (0.65) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL575659 | 0.76 | CYP3A4 (0.52) | CYP3A4ALDH1A1TSHR | |
| SCHEMBL22578316 | 0.74 | CYP3A4 (0.39) | CYP3A4ALDH1A1TSHRLMNAALOX15 | |
| SCHEMBL7634088 | 0.74 | CYP3A4 (0.39) | CYP3A4ALDH1A1TSHRLMNAALOX15 | |
| SCHEMBL19857507 | 0.74 | CYP3A4 (0.39) | CYP3A4ALDH1A1TSHRLMNAALOX15 | |
| SCHEMBL2773549 | 0.74 | CYP3A4 (0.39) | CYP3A4ALDH1A1TSHRLMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053114-B2 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-6797725-B2 | SUCH AS 4-METHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLILDENEMETHYL)-1H-PYRROLE-2-CARBOXYLIC ACID FOR PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS; ANTICANCER AGENTS | SUGEN, INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | CYP3A4 2122/4885ALDH1A1 1738/4885TSHR 2616/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | CYP3A4 2122/4885ALDH1A1 1738/4885TSHR 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.